Cargando…

Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose

Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine’s effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the t...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Marte, Paola, Soto-González, Alondra, Ramos-Tollinchi, Lizzie, Torres-Jorge, Stephan, Ferre, Mariana, Rodríguez-Martinó, Esteban, Torres, Esther A., Sariol, Carlos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414888/
https://www.ncbi.nlm.nih.gov/pubmed/36016189
http://dx.doi.org/10.3390/vaccines10081301
_version_ 1784776097603256320
author López-Marte, Paola
Soto-González, Alondra
Ramos-Tollinchi, Lizzie
Torres-Jorge, Stephan
Ferre, Mariana
Rodríguez-Martinó, Esteban
Torres, Esther A.
Sariol, Carlos A.
author_facet López-Marte, Paola
Soto-González, Alondra
Ramos-Tollinchi, Lizzie
Torres-Jorge, Stephan
Ferre, Mariana
Rodríguez-Martinó, Esteban
Torres, Esther A.
Sariol, Carlos A.
author_sort López-Marte, Paola
collection PubMed
description Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine’s effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the third vaccine dose can neutralize SARS-CoV-2 variants in this population remains unknown. This study aims to evaluate the humoral response of SARS-CoV-2 variants in patients with IBD 60 days after the third vaccine dose [BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)]. Fifty-six subjects with IBD and 12 healthy subjects were recruited. Ninety percent of patients with IBD (49/56) received biologics and/or immunomodulatory therapy. Twenty-four subjects with IBD did not develop effective neutralizing capability against the Omicron variant. Seventy percent (17/24) of those subjects received anti-tumor necrosis factor therapy [10 = adalimumab, 7 = infliximab], two of which had a history of COVID-19 infection, and one subject did not develop immune neutralization against three other variants: Gamma, Epsilon, and Kappa. All subjects in the control group developed detectable antibodies and effective neutralization against all seven SARS-CoV-2 variants. Our study shows that patients with IBD might not be protected against SARS-CoV-2 variants, and more extensive studies are needed to evaluate optimal immunity.
format Online
Article
Text
id pubmed-9414888
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94148882022-08-27 Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose López-Marte, Paola Soto-González, Alondra Ramos-Tollinchi, Lizzie Torres-Jorge, Stephan Ferre, Mariana Rodríguez-Martinó, Esteban Torres, Esther A. Sariol, Carlos A. Vaccines (Basel) Article Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine’s effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the third vaccine dose can neutralize SARS-CoV-2 variants in this population remains unknown. This study aims to evaluate the humoral response of SARS-CoV-2 variants in patients with IBD 60 days after the third vaccine dose [BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)]. Fifty-six subjects with IBD and 12 healthy subjects were recruited. Ninety percent of patients with IBD (49/56) received biologics and/or immunomodulatory therapy. Twenty-four subjects with IBD did not develop effective neutralizing capability against the Omicron variant. Seventy percent (17/24) of those subjects received anti-tumor necrosis factor therapy [10 = adalimumab, 7 = infliximab], two of which had a history of COVID-19 infection, and one subject did not develop immune neutralization against three other variants: Gamma, Epsilon, and Kappa. All subjects in the control group developed detectable antibodies and effective neutralization against all seven SARS-CoV-2 variants. Our study shows that patients with IBD might not be protected against SARS-CoV-2 variants, and more extensive studies are needed to evaluate optimal immunity. MDPI 2022-08-11 /pmc/articles/PMC9414888/ /pubmed/36016189 http://dx.doi.org/10.3390/vaccines10081301 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
López-Marte, Paola
Soto-González, Alondra
Ramos-Tollinchi, Lizzie
Torres-Jorge, Stephan
Ferre, Mariana
Rodríguez-Martinó, Esteban
Torres, Esther A.
Sariol, Carlos A.
Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose
title Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose
title_full Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose
title_fullStr Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose
title_full_unstemmed Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose
title_short Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose
title_sort inefficient induction of neutralizing antibodies against sars-cov-2 variants in patients with inflammatory bowel disease on anti-tumor necrosis factor therapy after receiving a third mrna vaccine dose
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414888/
https://www.ncbi.nlm.nih.gov/pubmed/36016189
http://dx.doi.org/10.3390/vaccines10081301
work_keys_str_mv AT lopezmartepaola inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose
AT sotogonzalezalondra inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose
AT ramostollinchilizzie inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose
AT torresjorgestephan inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose
AT ferremariana inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose
AT rodriguezmartinoesteban inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose
AT torresesthera inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose
AT sariolcarlosa inefficientinductionofneutralizingantibodiesagainstsarscov2variantsinpatientswithinflammatoryboweldiseaseonantitumornecrosisfactortherapyafterreceivingathirdmrnavaccinedose